Suggested remit: To appraise the clinical and cost effectiveness of ravulizumab within its marketing authorisation for treating refractory antibody positive generalised myasthenia gravis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 4019

Provisional Schedule

Expected publication 22 November 2023

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Stakeholders

Companies sponsors Alexion (ravulizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Muscular Dystrophy UK
  myaware
Professional groups Association of British Neurologists
  Royal College of Physicians
  UK Clinical Pharmacy Association
Associated public health groups None
Comparator companies Bio Products Laboratory (plasma exchange) (confidentiality agreement not signed, not participating)
  Biotest UK (plasma exchange) (confidentiality agreement not signed, not participating)
  CSL Behring UK (human immunoglobulin plasma exchange) (confidentiality agreement not signed, not participating)
  Grifols UK (immunoglobulin, plasma exchange) (confidentiality agreement not signed, not participating)
  Napp Pharmaceutical (rituximab) (confidentiality agreement not signed, not participating)
  Octapharma (plasma exchange) (confidentiality agreement not signed, not participating)
  Pfizer (rituximab) (confidentiality agreement not signed, not participating)
  Roche (rituximab) (confidentiality agreement not signed, not participating)
  Sandoz (rituximab) (confidentiality agreement not signed, not participating)
  Teva UK (plasma exchange) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
13 September 2023 Committee meeting: 1
01 September 2022 Invitation to participate
03 May 2022 (14:00) Scoping workshop
15 March 2022 - 12 April 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
15 March 2022 In progress. Scoping commenced
24 November 2021 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual